Shifting patterns of inhaled antibiotic use in cystic fibrosis
- 30 July 2008
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 43 (9) , 874-881
Abstract
Rationale: Antibiotic inhalation has become widely accepted as a standard treatment for cystic fibrosis (CF) airway infection. We assessed the prevalence and context of inhaled antibiotic use in the North American CF population. Our working hypothesis was that a shift from acute to chronic use of inhaled antibiotics has coincided with increased prevalence of use among CF patients.Methods: Descriptive statistics were collected for 30,833 patients enrolled in the Epidemiologic Study of CF (ESCF) during 1996 through 2005. A multivariate analysis was performed on data from a subgroup of 18,021 patients enrolled in ESCF during 2003 through 2005.Results: The prevalence of inhaled antibiotic use in the North American CF population increased during 1996 through 2005 due to increased chronic use, while acute use to treat pulmonary exacerbations decreased. In 2005, 50% of CF patients used inhaled tobramycin and 9% used inhaled colistin chronically; most of the latter used both agents concurrently. Airway obstruction severity and airway infection status were predictors of inhaled antibiotic use.Conclusions: Increased chronic use and decreased acute use of inhaled antibiotics presumably reflect a shift toward more proactive management of airway infections in the North American CF population. The effects of these usage patterns on long‐term clinical outcomes and emergence of antibiotic‐resistant Pseudomonas aeruginosa strains warrant further study. Pediatr Pulmonol. 2008; 43:874–881.Keywords
This publication has 40 references indexed in Scilit:
- Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patientsClinical Microbiology and Infection, 2005
- PmrAB, a Two-Component Regulatory System of Pseudomonas aeruginosa That Modulates Resistance to Cationic Antimicrobial Peptides and Addition of Aminoarabinose to Lipid AJournal of Bacteriology, 2004
- Nebulised anti-pseudomonal antibiotics for cystic fibrosis2003
- Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosisPediatric Pulmonology, 2002
- Gender differences in cystic fibrosis: Pseudomonas aeruginosa infectionJournal of Clinical Epidemiology, 1995
- Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosisPediatric Pulmonology, 1989
- Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosisThe Journal of Pediatrics, 1987
- Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infectionJournal of Antimicrobial Chemotherapy, 1987
- Purification of the galactose‐binding hemagglutinin of Pseudomonas aeruginosa by affinity column chromatography using sepharoseFEBS Letters, 1972
- Carbenicillin in patients with cystic fibrosis:Clinical pharmacology and therapeutic evaluationThe Journal of Pediatrics, 1971